Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAAXB1648

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:03:08 ON 05 MAR 2008

=> FIL MEDLINE BIOSIS CAPLUS CA USPATFULL
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 17:03:30 ON 05 MAR 2008

FILE 'BIOSIS' ENTERED AT 17:03:30 ON 05 MAR 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 17:03:30 ON 05 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CA' ENTERED AT 17:03:30 ON 05 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:03:30 ON 05 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s CDR and SDR and alanine and replacing and affinity and grafting
L1 38 CDR AND SDR AND ALANINE AND REPLACING AND AFFINITY AND GRAFTING

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2 38 DUP REM L1 (0 DUPLICATES REMOVED)

=> d ibib ab l2 1-38

L2 ANSWER 1 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2008:43630 USPATFULL
TITLE: Profilin and related immunomodulatory ligands
INVENTOR(S): Zlatkin, Igor, Lansing, MI, UNITED STATES
McCormick, J. Justin, Port Austin, MI, UNITED STATES
PATENT ASSIGNEE(S): Michigan State University, East Lansing, MI, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2008038250	A1	20080214	
APPLICATION INFO.:	US 2006-641084	A1	20061218	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-751195P	20051216 (60)
	US 2006-801036P	20060517 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILMERHALE/BOSTON, 60 STATE STREET, BOSTON, MA, 02109,

US
NUMBER OF CLAIMS: 78
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 82 Drawing Page(s)
LINE COUNT: 10613
AB The invention provides profilin-related immunomodulatory polypeptides and toll-like receptor agonists, as well as related pharmaceutical compositions and methods of treatment, useful for treating cancer and infectious disease.

L2 ANSWER 2 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2007:296967 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
Ballance, David J., Berwyn, PA, UNITED STATES
Turner, Andrew J., King Of Prussia, PA, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
Delta Biotechnology Limited, Nottingham, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007259815	A1	20071108
APPLICATION INFO.:	US 2007-783419	A1	20070409 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2006-429373, filed on 8 May 2006, GRANTED, Pat. No. US 7238667 Continuation of Ser. No. US 2004-775204, filed on 11 Feb 2004, GRANTED, Pat. No. US 7141547 Continuation of Ser. No. WO 2002-US40891, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-350358P	20020124 (60)
	US 2002-351360P	20020128 (60)
	US 2002-359370P	20020226 (60)
	US 2002-360000P	20020228 (60)
	US 2002-367500P	20020327 (60)
	US 2002-370227P	20020408 (60)
	US 2002-378950P	20020510 (60)
	US 2002-382617P	20020524 (60)
	US 2002-383123P	20020528 (60)
	US 2002-385708P	20020605 (60)
	US 2002-394625P	20020710 (60)
	US 2002-398008P	20020724 (60)
	US 2002-402131P	20020809 (60)
	US 2002-402708P	20020813 (60)
	US 2002-411426P	20020918 (60)
	US 2002-411355P	20020918 (60)
	US 2002-414984P	20021002 (60)
	US 2002-417611P	20021011 (60)
	US 2002-420246P	20021023 (60)
	US 2002-423623P	20021105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 24746
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L2 ANSWER 3 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2007:278614 USPATFULL
TITLE:	Albumin fusion proteins
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES Ruben, Steven M., Brookeville, MD, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation) Delta Biotechnology Limited, Nottingham, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007244047	A1	20071018
APPLICATION INFO.:	US 2007-714841	A1	20070307 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2006-429276, filed on 8 May 2006, PENDING Continuation of Ser. No. US 2004-775204, filed on 11 Feb 2004, GRANTED, Pat. No. US 7141547 Continuation of Ser. No. WO 2002-US40891, filed on 23 Dec 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-350358P	20020124 (60)
	US 2002-351360P	20020128 (60)
	US 2002-359370P	20020226 (60)
	US 2002-360000P	20020228 (60)
	US 2002-367500P	20020327 (60)
	US 2002-370227P	20020408 (60)
	US 2002-378950P	20020510 (60)
	US 2002-382617P	20020524 (60)
	US 2002-383123P	20020528 (60)
	US 2002-385708P	20020605 (60)
	US 2002-394625P	20020710 (60)
	US 2002-398008P	20020724 (60)
	US 2002-402131P	20020809 (60)
	US 2002-402708P	20020813 (60)
	US 2002-411355P	20020918 (60)
	US 2002-411426P	20020918 (60)
	US 2002-414984P	20021002 (60)
	US 2002-417611P	20021011 (60)
	US 2002-420246P	20021023 (60)
	US 2002-423623P	20021105 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 24858
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L2 ANSWER 4 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2007:256245 USPATFULL
TITLE: Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
INVENTOR(S): Kulaksiz, Hasan, Heidelberg, GERMANY, FEDERAL REPUBLIC OF
Geacintov, Cyril E., Mountainside, NJ, UNITED STATES
Jentzko, Alfred, Butzbach/Nieder-Weisel, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007224186	A1	20070927
APPLICATION INFO.:	US 2007-657772	A1	20070125 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-441089, filed on 19 May 2003, PENDING Continuation-in-part of Ser. No. US 2002-299486, filed on 19 Nov 2002, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOX ROTHSCHILD LLP, PRINCETON PIKE CORPORATE CENTER, 997 LENOX DRIVE, BUILDING #3, LAWRENCEVILLE, NJ, 08648, US
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 3597
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and/or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 60 and 84, or, in another embodiment, amino acids 74 and 81, as aligned with the human pre-pro-hepcidin precursor protein, and quantifying the pro-hepcidin and/or mature hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin/mature hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.

L2 ANSWER 5 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2007:217656 USPATFULL
TITLE: Novel essential fungal polynucleotides, polypeptides, and methods of use
INVENTOR(S): Wang, Ying-Kai, Rocky Hill, CT, UNITED STATES
Liu, Mengping, North Haven, CT, UNITED STATES
Dougherty, Brian A., Killingworth, CT, UNITED STATES
Healy, Matthew D., Hamden, CT, UNITED STATES
Davison, Daniel B., Morrisville, PA, UNITED STATES
Mazzucco, Charles E., Branford, CT, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Maurice, Trina C., Bristol, CT, UNITED STATES
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007190613	A1	20070816
APPLICATION INFO.:	US 2007-725755	A1	20070320 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2003-424324, filed on 25 Apr 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-376022P	20020426 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1-30
NUMBER OF DRAWINGS: 67 Drawing Page(s)
LINE COUNT: 26196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides essential fungal polynucleotides and their encoded polypeptides, homologues thereof and their uses. Additionally, the invention provides methods for the identification of essential polynucleotides and fungal strains which may be used for drug screening.

L2 ANSWER 6 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2007:197538 USPATFULL
TITLE: Novel essential fungal polynucleotides, polypeptides, and methods of use
INVENTOR(S): Wang, Ying-Kai, Rocky Hill, CT, UNITED STATES
Liu, Mengping, North Haven, CT, UNITED STATES
Dougherty, Brian A., Killingworth, CT, UNITED STATES
Healy, Matthew D., Hamden, CT, UNITED STATES
Davison, Daniel B., Morrisville, PA, UNITED STATES
Mazzucco, Charles E., Branford, CT, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Maurice, Trina C., Bristol, CT, UNITED STATES
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007172881	A1	20070726
APPLICATION INFO.:	US 2007-726434	A1	20070322 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2003-424324, filed on 25 Apr 2003, PENDING

	NUMBER	DATE

PRIORITY INFORMATION:	US 2002-376022P	20020426 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1-30	
NUMBER OF DRAWINGS:	67 Drawing Page(s)	
LINE COUNT:	26191	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides essential fungal polynucleotides and their encoded polypeptides, homologues thereof and their uses. Additionally, the invention provides methods for the identification of essential polynucleotides and fungal strains which may be used for drug screening.

L2 ANSWER 7 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2007:75497 USPATFULL
TITLE:	26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor
INVENTOR(S):	Meyers, Rachel E., Newton, MA, UNITED STATES MacBeth, Kyle J., Boston, MA, UNITED STATES Curtis, Rory A.J., Ashland, MA, UNITED STATES Rudolph-Owen, Laura A., Medford, MA, UNITED STATES Weich, Nadine S., Brookline, MA, UNITED STATES Olandt, Peter J., Buffalo, NY, UNITED STATES Tsai, Fong-Ying, Newton, MA, UNITED STATES Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES Carroll, Joseph M., Cambridge, MA, UNITED STATES
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007065848	A1	20070322
APPLICATION INFO.:	US 2006-493347	A1	20060726 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-410764, filed on 10 Apr 2003, ABANDONED Continuation-in-part of Ser. No. US 2001-924358, filed on 6 Aug 2001, ABANDONED Continuation-in-part of Ser. No. US 2003-350553, filed on 24 Jan 2003, ABANDONED Continuation-in-part of Ser. No. US 2001-966614, filed on 27 Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-281094, filed on 25 Oct 2002, ABANDONED Continuation-in-part of Ser. No. US 2002-76535, filed on 15 Feb 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-860352, filed on 17 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-593927, filed on 15 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-226410, filed on 23 Aug 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-997816, filed on 29 Nov 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-686673, filed on 11 Oct 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-229300P	20000901 (60)
	US 2002-351572P	20020124 (60)
	US 2000-238054P	20001005 (60)
	US 2001-347815P	20011029 (60)

	US 2001-269440P 20010216 (60)
	US 2000-205301P 20000519 (60)
	US 2000-199391P 20000425 (60)
	US 2001-314884P 20010824 (60)
	US 2000-250186P 20001130 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139, US
NUMBER OF CLAIMS:	19
EXEMPLARY CLAIM:	1
LINE COUNT:	17218

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L2 ANSWER 8 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2007:55341 USPATFULL
TITLE:	Albumin fusion proteins
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES Moore, Paul A., North Bethesda, MD, UNITED STATES Bock, Jason B., North Potomac, MD, UNITED STATES Bell, Adam, Germantown, MD, UNITED STATES Shi, Yanggu, Gaithersburg, MD, UNITED STATES LaFleur, David W., Washington, DC, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007048282	A1	20070301
APPLICATION INFO.:	US 2006-500314	A1	20060808 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2005-US4041, filed on 9 Feb 2005, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-542274P	20040209 (60)
	US 2004-549901P	20040305 (60)
	US 2004-556906P	20040329 (60)
	US 2004-636603P	20041217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 17888
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L2 ANSWER 9 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2007:43684 USPATFULL
TITLE: Computer systems and methods for inferring casuality from cellular constituent abundance data
INVENTOR(S): Schadt, Eric E., Kirkland, WA, UNITED STATES
Lamb, John, Shoreline, WA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2007038386	A1	20070215	
APPLICATION INFO.:	US 2004-567282	A1	20040604	(10)
	WO 2004-US17754		20040604	
			20060822	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492682P	20030805 (60)
	US 2003-497470P	20030821 (60)
	US 2004-575499P	20040528 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
NUMBER OF CLAIMS: 104
EXEMPLARY CLAIM: 1-88
NUMBER OF DRAWINGS: 60 Drawing Page(s)
LINE COUNT: 12602
AB Methods, computer program products, and systems are provided for associating a cellular constituent with a trait T exhibited by a species. A cellular constituent i that has at least one abundance quantitative trait locus (eQTL) coincident with a respective clinical quantitative trait locus (cQTL) for the trait of interest T is identified. For each eQTL, a determination is made as to whether (i) the genetic variation of the eQTL and (ii) the variation of the trait of interest T across the plurality of organisms are correlated conditional on an abundance pattern of the cellular constituent i across the plurality of organisms. When the genetic variation of (i) one of the eQTL and (ii) the variation of the trait of interest T across the plurality of organisms are uncorrelated conditional on the abundance pattern of the cellular constituent i, the cellular constituent i is considered causal for, and is therefore associated with, the trait of interest T.

L2 ANSWER 10 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2007:31031 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007027306	A1	20070201
APPLICATION INFO.:	US 2006-500508	A1	20060808 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2005-US4041, filed on 9 Feb 2005, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-542274P	20040209 (60)
	US 2004-549901P	20040305 (60)
	US 2004-556906P	20040329 (60)
	US 2004-636603P	20041217 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 17715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L2 ANSWER 11 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2007:24550 USPATFULL
TITLE: Humanized antibody amd process for preparing same
INVENTOR(S): Hong, Hyo Jeong, 117-201 CROVA APT., DUNSAN-1-DONG, SEO GU, DAEJEON, KOREA, REPUBLIC OF 302-772

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007021595	A1	20070125
APPLICATION INFO.:	US 2003-508759	A1	20030322 (10)
	WO 2003-KR564		20030322
			20040922 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	KR 2002-15708	20020322

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ANDERSON, KILL & OLICK, P.C., 1251 AVENUE OF THE AMERICAS, NEW YORK,, NY, 10020-1182, US
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1439
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A humanized antibody is produced by process comprising the steps of: (a) selecting a specificity determining residue (SDR) of the complementarity determining region (CDR) of murine monoclonal

antibody heavy chain and light chain variable regions; and (b) grafting said SDR to at least one of the corresponding amino acid sequences in human antibody variable regions.

L2 ANSWER 12 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2007:18189 USPATFULL
TITLE:	Novel essential fungal polynucleotides, polypeptides, and methods of use
INVENTOR(S):	Wang, Ying-Kai, Rocky Hill, CT, UNITED STATES Liu, Mengping, North Haven, CT, UNITED STATES Dougherty, Brian A., Killingworth, CT, UNITED STATES Healy, Matthew D., Hamden, CT, UNITED STATES Davison, Daniel B., Yardley, PA, UNITED STATES Mazzucco, Charles E., Branford, CT, UNITED STATES Krystek, Stanley R., Ringoes, NJ, UNITED STATES Bassolino, Donna A., Hamilton, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007015906	A1	20070118
APPLICATION INFO.:	US 2003-424324	A1	20030425 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-376022P	20020426 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
NUMBER OF CLAIMS:	30
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	67 Drawing Page(s)
LINE COUNT:	15627

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides essential fungal polynucleotides and their encoded polypeptides, homologues thereof and their uses. Additionally, the invention provides methods for the identification of essential polynucleotides and fungal strains which may be used for drug screening.

L2 ANSWER 13 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2007:17486 USPATFULL
TITLE:	Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor
INVENTOR(S):	Glucksmann, Maria A., Lexington, MA, UNITED STATES Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES Carroll, Joseph M., Cambridge, MA, UNITED STATES Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007015201	A1	20070118
APPLICATION INFO.:	US 2006-522789	A1	20060918 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-407079, filed on 3 Apr 2003, PENDING Continuation-in-part of Ser. No. US 2002-226102, filed on 22 Aug 2002, ABANDONED Continuation-in-part of Ser. No. US 2002-225094, filed on 21 Aug 2002, ABANDONED Continuation-in-part of Ser. No. US 2002-272417, filed on 15 Oct 2002, ABANDONED Continuation of Ser. No. US 2000-715790, filed on 17 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US

2002-282837, filed on 29 Oct 2002, ABANDONED
Continuation of Ser. No. US 2001-796338, filed on 28 Feb 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-863200, filed on 22 May 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-314041P	20010822 (60)
	US 2001-314185P	20010822 (60)
	US 2000-191845P	20000324 (60)
	US 2000-186059P	20000229 (60)
	US 2000-206019P	20000522 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 12186
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L2 ANSWER 14 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2006:334023 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006286635	A1	20061221
	US 7238660	B2	20070703
APPLICATION INFO.:	US 2006-393893	A1	20060331 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-775180, filed on 11 Feb 2004, PENDING Continuation of Ser. No. WO 2002-US40892, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-360000P	20020228 (60)
	US 2002-378950P	20020510 (60)
	US 2002-398008P	20020724 (60)
	US 2002-411355P	20020918 (60)
	US 2002-414984P	20021002 (60)
	US 2002-417611P	20021011 (60)
	US 2002-420246P	20021023 (60)
	US 2002-423623P	20021105 (60)

	US 2002-350358P 20020124 (60)
	US 2002-359370P 20020226 (60)
	US 2002-367500P 20020327 (60)
	US 2002-402131P 20020809 (60)
	US 2002-402708P 20020813 (60)
	US 2002-370227P 20020408 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS:	32
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	13 Drawing Page(s)
LINE COUNT:	20492

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

L2 ANSWER 15 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2006:322351 USPATFULL
TITLE:	Albumin fusion proteins
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES Ruben, Steven M., Brookeville, MD, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006276396	A1	20061207
	US 7238667	B2	20070703
APPLICATION INFO.:	US 2006-429373	A1	20060508 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-775204, filed on 11 Feb 2004, PENDING Continuation of Ser. No. WO 2002-US40891, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-350358P	20020124 (60)
	US 2002-351360P	20020128 (60)
	US 2002-359370P	20020226 (60)
	US 2002-360000P	20020228 (60)
	US 2002-367500P	20020327 (60)
	US 2002-370227P	20020408 (60)
	US 2002-378950P	20020510 (60)
	US 2002-382617P	20020524 (60)
	US 2002-383123P	20020528 (60)
	US 2002-385708P	20020605 (60)
	US 2002-394625P	20020710 (60)
	US 2002-398008P	20020724 (60)
	US 2002-402131P	20020809 (60)
	US 2002-402708P	20020813 (60)
	US 2002-411355P	20020918 (60)

	US 2002-411426P	20020918 (60)
	US 2002-414984P	20021002 (60)
	US 2002-417611P	20021011 (60)
	US 2002-420246P	20021023 (60)
	US 2002-423623P	20021105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Page(s)	
LINE COUNT:	24781	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

L2 ANSWER 16 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2006:282923 USPATFULL
TITLE:	Computer systems and methods for inferring causality from cellullar constituent abundance data
INVENTOR(S):	Schadt, Eric E., Kirkland, WA, UNITED STATES Lamb, John, Shoreline, WA, UNITED STATES
PATENT ASSIGNEE(S):	Rosetta Inpharmatics LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006241869	A1	20061026
APPLICATION INFO.:	US 2006-361871	A1	20060223 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-567282, PENDING A 371 of International Ser. No. WO 2004-US17754, filed on 4 Jun 2004		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-492682P	20030805 (60)
	US 2003-497470P	20030821 (60)
	US 2004-575499P	20040528 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	89 Drawing Page(s)	
LINE COUNT:	11763	

AB Methods for determining whether a molecule affects a disorder are provided. A cell from an organism is contacted with the molecule, or the molecule is expressed within the cell. A determination is made as to whether the RNA or protein expression in the cell of at least one open reading frame is changed relative to the expression of the reading frame in the absence of the molecule. Each such open reading frame is regulated by a promoter native to SEQ ID NOS: 5-9, 11-12, 14, 16, 18, 20-21, 23, 25, 27, 29, 31, 33 or homologs of the foregoing. A determination is made as to whether the molecule affects the disorder

when the RNA or protein expression of the at least one reading frame is changed. Alternatively, a determination is made that the molecule does not affect the disorder when the RNA or protein expression of the at least one reading frame is unchanged.

L2 ANSWER 17 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2006:228368 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
Ballance, David J., Berwyn, PA, UNITED STATES
Turner, Andrew J., King of Prussia, PA, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
Delta Biotechnology Limited, Nottingham, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006194735	A1	20060831
APPLICATION INFO.:	US 2006-429276	A1	20060508 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-775204, filed on 11 Feb 2004, PENDING Continuation of Ser. No. WO 2002-US40891, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-350358P	20020124 (60)
	US 2002-351360P	20020128 (60)
	US 2002-359370P	20020226 (60)
	US 2002-360000P	20020228 (60)
	US 2002-367500P	20020327 (60)
	US 2002-370227P	20020408 (60)
	US 2002-378950P	20020510 (60)
	US 2002-382617P	20020524 (60)
	US 2002-383123P	20020528 (60)
	US 2002-385708P	20020605 (60)
	US 2002-394625P	20020710 (60)
	US 2002-398008P	20020724 (60)
	US 2002-402131P	20020809 (60)
	US 2002-402708P	20020813 (60)
	US 2002-411355P	20020918 (60)
	US 2002-411426P	20020918 (60)
	US 2002-414984P	20021002 (60)
	US 2002-417611P	20021011 (60)
	US 2002-420246P	20021023 (60)
	US 2002-423623P	20021105 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 23 Drawing Page(s)

LINE COUNT: 24486

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and

methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

L2 ANSWER 18 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2006:202057 USPATFULL
TITLE: Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
INVENTOR(S): Kashmiri, Syed V. S., Gaithersburg, MD, UNITED STATES
Schlom, Jffrey, Potomac, MD, UNITED STATES
Padlan, Eduardo A., Kensington, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006171941	A1	20060803	
APPLICATION INFO.:	US 2004-570220	A1	20040827	(10)
	WO 2004-US28004		20040827	
			20060228	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-498903P	20030829 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KLARQUIST SPARKMAN, LLP, 121 S.W. SALMON STREET, SUITE #1600, PORTLAND, OR, 97204-2988, US
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 3113
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28' CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72.

L2 ANSWER 19 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2006:194925 USPATFULL
TITLE: Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors
INVENTOR(S): Kashmiri, Syed V.S., Gaithersburg, MD, UNITED STATES
Schlom, Jeffrey, Potomac, MD, UNITED STATES
Padlan, Eduardo A., Kensington, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006165680	A1	20060727	
APPLICATION INFO.:	US 2003-519580	A1	20030626	(10)
	WO 2003-US20367		20030626	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-60393077	20020628
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KLARQUIST SPARKMAN, LLP, 121 S.W. SALMON STREET, SUITE #1600, PORTLAND, OR, 97204-2988, US	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	2097	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.

L2 ANSWER 20 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2006:104804 USPATFULL
TITLE:	Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor
INVENTOR(S):	Meyers, Rachel E., Newton, MA, UNITED STATES Williamson, Mark J., Saugus, MA, UNITED STATES Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES MacBeth, Kyle J., Boston, MA, UNITED STATES Hunter, John Joseph, Somerville, MA, UNITED STATES Rudolph-Owen, Laura A., Medford, MA, UNITED STATES Bandaru, Rajasekhar, Watertown, MA, UNITED STATES Tsai, Fong-Ying, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006088907	A1	20060427
APPLICATION INFO.:	US 2003-370959	A1	20030220 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-910150, filed on 18 Jul 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-219028P	20000718 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Paul J. Paglierani, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139, US	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	15824	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 proteins, fusion proteins, antigenic peptides and anti-13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L2 ANSWER 21 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2006:15872 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Haseltine, William A., Washington, DC, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006014254	A1	20060119
APPLICATION INFO.:	US 2005-175690	A1	20050707 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2004-US1369, filed on 20 Jan 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-441305P	20030122 (60)
	US 2003-453201P	20030311 (60)
	US 2003-467222P	20030502 (60)
	US 2003-472816P	20030523 (60)
	US 2003-476267P	20030606 (60)
	US 2003-505172P	20030924 (60)
	US 2003-506746P	20030930 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 11 Drawing Page(s)

LINE COUNT: 17653

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising

albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L2 ANSWER 22 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2005:247698 USPATFULL
TITLE:	Novel human genes and methods of use thereof
INVENTOR(S):	Meyers, Rachel E., Newton, MA, UNITED STATES Curtis, Rory A.J., Ashland, MA, UNITED STATES Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES Bandaru, Rajasekhar, Watertown, MA, UNITED STATES Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005214893	A1	20050929
APPLICATION INFO.:	US 2004-968812	A1	20041019 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-176306, filed on 20 Jun 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-1137, filed on 14 Nov 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US45291, filed on 14 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-23617, filed on 18 Dec 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US49416, filed on 18 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-83248, filed on 22 Oct 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US46717	20011022
	US 2000-248362P	20001114 (60)
	US 2000-248331P	20001114 (60)
	US 2000-248365P	20001114 (60)
	US 2000-250077P	20001130 (60)
	US 2000-250327P	20001130 (60)
	US 2000-250176P	20001130 (60)
	US 2000-256249P	20001218 (60)
	US 2000-256405P	20001218 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139, US
NUMBER OF CLAIMS:	16
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	60 Drawing Page(s)
LINE COUNT:	26559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 47476, 67210, 49875,46842,33201, 83378,84233,64708, 85041,84234,21617, 55562,23566,33489, and 57779 nucleic acid molecules, which encode novel human genes. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 gene has been introduced or disrupted. The invention still further provides isolated

47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 proteins, fusion proteins, antigenic peptides and anti-47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

L2 ANSWER 23 OF 38 USPATFULL on STN

ACCESSION NUMBER: 2005:214989 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
Ballance, David J., Berwyn, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005186664	A1	20050825
	US 7141547	B2	20061128
APPLICATION INFO.:	US 2004-775204	A1	20040211 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2002-US40891, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-350358P	20020124 (60)
	US 2002-351360P	20020128 (60)
	US 2002-359370P	20020226 (60)
	US 2002-360000P	20020228 (60)
	US 2002-367500P	20020327 (60)
	US 2002-370227P	20020408 (60)
	US 2002-378950P	20020510 (60)
	US 2002-382617P	20020524 (60)
	US 2002-383123P	20020528 (60)
	US 2002-385708P	20020605 (60)
	US 2002-394625P	20020710 (60)
	US 2002-398008P	20020724 (60)
	US 2002-402131P	20020809 (60)
	US 2002-402708P	20020813 (60)
	US 2002-411355P	20020918 (60)
	US 2002-411426P	20020918 (60)
	US 2002-414984P	20021002 (60)
	US 2002-417611P	20021011 (60)
	US 2002-420246P	20021023 (60)
	US 2002-423623P	20021105 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 23 Drawing Page(s)

LINE COUNT: 25129

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising

albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

L2 ANSWER 24 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2005:63530 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005054570	A1	20050310
	US 7189690	B2	20070313
APPLICATION INFO.:	US 2004-775180	A1	20040211 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2002-US40892, filed on 23 Dec 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341811P	20011221 (60)
	US 2002-360000P	20020228 (60)
	US 2002-378950P	20020510 (60)
	US 2002-398008P	20020724 (60)
	US 2002-411355P	20020918 (60)
	US 2002-414984P	20021002 (60)
	US 2002-417611P	20021011 (60)
	US 2002-420246P	20021023 (60)
	US 2002-423623P	20021105 (60)
	US 2002-350358P	20020124 (60)
	US 2002-359370P	20020226 (60)
	US 2002-367500P	20020327 (60)
	US 2002-402131P	20020809 (60)
	US 2002-402708P	20020813 (60)
	US 2002-370227P	20020408 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 20949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

L2 ANSWER 25 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2004:171926 USPATFULL
TITLE: Novel human enzyme family members and uses thereof
INVENTOR(S): Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksmann, Maria Alexandria, Lexington, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA, 02139 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20041320870	A1	20040708
APPLICATION INFO.:	US 2004-776871	A1	20040211 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-175696, filed on 20 Jun 2002, PENDING Continuation-in-part of Ser. No. US 2002-67668, filed on 4 Feb 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-823901, filed on 30 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US10720, filed on 2 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2001-862658, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US16380, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. US 2001-882837, filed on 15 Jun 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US19319, filed on 15 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-266140P	20010202 (60)
	US 2000-193920P	20000331 (60)
	US 2000-205675P	20000519 (60)
	US 2000-211727P	20000615 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 21375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 33312, 33303, 32579, 21509, 33770, 46638, and 50090 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33312, 33303, 32579, 21509, 33770, 46638, or 50090 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33312, 33303, 32579, 21509, 33770, 46638, or 50090 gene has been introduced or disrupted. The invention still further provides isolated 33312, 33303, 32579, 21509, 33770, 46638, or 50090 proteins, fusion proteins, antigenic peptides and anti-33312, 33303, 32579, 21509, 33770, 46638, or 50090 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

L2 ANSWER 26 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2004:63776 USPATFULL
TITLE: 31 human secreted proteins
INVENTOR(S): Ruben, Steven M., Brookeville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Komatsoulis, George, Silver Spring, MD, UNITED STATES

Endress, Gregory A., Florence, MA, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences,Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004048294	A1	20040311
APPLICATION INFO.:	US 2003-607565	A1	20030627 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-820893, filed on 30 Mar 2001, ABANDONED Continuation of Ser. No. US 2000-531119, filed on 20 Mar 2000, ABANDONED Continuation-in-part of Ser. No. WO 1999-US22012, filed on 22 Sep 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101546P	19980923 (60)
	US 1998-102895P	19981002 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 17193
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

L2 ANSWER 27 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2004:44517 USPATFULL
TITLE: Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor
INVENTOR(S): Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Hunter, John Joseph, Somerville, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004033509	A1	20040219
APPLICATION INFO.:	US 2003-377097	A1	20030228 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-910150, filed on 18 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-251507, filed on 20 Sep 2002, PENDING

	NUMBER	DATE

PRIORITY INFORMATION: US 2000-219028P 20000718 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 15960
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 proteins, fusion proteins, antigenic peptides and anti-13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L2 ANSWER 28 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2004:7430 USPATFULL
TITLE: Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 molecules and uses therefor
INVENTOR(S): Meyers, Rachel E., Newton, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Curtis, Rory A. J., Ashland, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Weich, Nadine S., Brookline, MA, UNITED STATES
Olandt, Peter J., Buffalo, NY, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Carroll, Joseph M., Cambridge, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005664	A1	20040108
APPLICATION INFO.:	US 2003-410764	A1	20030410 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-924358, filed on 6 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2003-350553, filed on 24 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-966614, filed on 27 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2002-281094, filed on 25 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2002-76535, filed on 15 Feb 2002, PENDING Continuation-in-part of Ser. No. US 2001-860352, filed on 17 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-593927, filed on 15 Jun 2000, ABANDONED Continuation-in-part of Ser.

No. US 2002-226410, filed on 23 Aug 2002, PENDING
Continuation-in-part of Ser. No. US 2001-997816, filed on 29 Nov 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-686673, filed on 11 Oct 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-229300P	20000901 (60)
	US 2002-351572P	20020124 (60)
	US 2000-238054P	20001005 (60)
	US 2001-347815P	20011029 (60)
	US 2001-269440P	20010216 (60)
	US 2000-205301P	20000519 (60)
	US 2000-199391P	20000425 (60)
	US 2001-314884P	20010824 (60)
	US 2000-250186P	20001130 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 17049
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L2 ANSWER 29 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2003:312209 USPATFULL
TITLE: Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
INVENTOR(S): Glucksmann, Maria A., Lexington, MA, UNITED STATES
Curtis, Rory A.J., Ashland, MA, UNITED STATES
Lora, Jose M., Arlington, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219806	A1	20031127
APPLICATION INFO.:	US 2003-391399	A1	20030318 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-789481, filed on 20 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-634669, filed on 8 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-583373, filed on 31 May 2000, ABANDONED Continuation-in-part of Ser.

No. US 2000-510706, filed on 22 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-309804, filed on 4 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2002-94214, filed on 8 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2001-828035, filed on 6 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-891762, filed on 26 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2002-245121, filed on 17 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2002-95139, filed on 11 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2001-957683, filed on 19 Sep 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-942447, filed on 29 Aug 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-62937, filed on 31 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2002-255532, filed on 26 Sep 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336936P	20011204 (60)
	US 2001-275078P	20010312 (60)
	US 2000-195734P	20000407 (60)
	US 2000-214176P	20000626 (60)
	US 2001-322983P	20010917 (60)
	US 2001-275172P	20010312 (60)
	US 2000-233537P	20000919 (60)
	US 2000-229036P	20000831 (60)
	US 2001-267076P	20010201 (60)
	US 2001-325854P	20010927 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 19893
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 gene has been introduced or disrupted. The invention still further provides isolated 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 proteins, fusion proteins, antigenic peptides and anti-18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L2 ANSWER 30 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2003:306426 USPATFULL
TITLE: Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor
INVENTOR(S): Glucksmann, Maria A., Lexington, MA, UNITED STATES
Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES
Carroll, Joseph M., Cambridge, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215860	A1	20031120
APPLICATION INFO.:	US 2003-407079	A1	20030403 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-226102, filed on 22 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-225094, filed on 21 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-272417, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 2000-715790, filed on 17 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 2002-282837, filed on 29 Oct 2002, PENDING Continuation of Ser. No. US 2001-796338, filed on 28 Feb 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-863200, filed on 22 May 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-314041P	20010822 (60)
	US 2001-314185P	20010822 (60)
	US 2000-191845P	20000324 (60)
	US 2000-186059P	20000229 (60)
	US 2000-206019P	20000522 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 12157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L2 ANSWER 31 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2003:265258 USPATFULL
TITLE: 15603, a human ion channel family member and uses therefor
INVENTOR(S): Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186273	A1	20031002
APPLICATION INFO.:	US 2002-309804	A1	20021204 (10)

	NUMBER	DATE

PRIORITY INFORMATION: US 2001-336936P 20011204 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Steven A. Bossone, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 4914
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 15603 nucleic acid molecules, which encode novel ion channel family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15603 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15603 gene has been introduced or disrupted. The invention still further provides isolated 15603 proteins, fusion proteins, antigenic peptides and anti-15603 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L2 ANSWER 32 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2003:251541 USPATFULL
TITLE: 55562 and 21617, novel human proteins and methods of use thereof
INVENTOR(S): Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003176330	A1	20030918
APPLICATION INFO.:	US 2001-23617	A1	20011218 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256249P	20001218 (60)
	US 2000-256405P	20001218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 6105
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 21617 and 55562 nucleic acid molecules, which encode novel dehydrogenase or tetratricopeptide repeat members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21617 or 55562 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21617 or 55562 gene has been introduced or disrupted. The invention still further provides isolated 21617 or 55562 proteins, fusion proteins, antigenic peptides and anti-21617 or 55562 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

L2 ANSWER 33 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2003:188692 USPATFULL
TITLE: Novel human genes and methods of use thereof
INVENTOR(S): Meyers, Rachel E., Newton, MA, UNITED STATES

Curtis, Rory A. J., Framingham, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003130485	A1	20030710
APPLICATION INFO.:	US 2002-176306	A1	20020620 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-1137, filed on 14 Nov 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US45291, filed on 14 Nov 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US49416	20011218
	WO 2001-US46717	20011022
	US 2000-248362P	20001114 (60)
	US 2000-248331P	20001114 (60)
	US 2000-248365P	20001114 (60)
	US 2000-250077P	20001130 (60)
	US 2000-250327P	20001130 (60)
	US 2000-250176P	20001130 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 60 Drawing Page(s)
LINE COUNT: 26835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, and 57779 nucleic acid molecules, which encode novel human genes. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 gene has been introduced or disrupted. The invention still further provides isolated 47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 proteins, fusion proteins, antigenic peptides and anti-47476, 67210, 49875, 46842, 33201, 83378, 84233, 64708, 85041, 84234, 21617, 55562, 23566, 33489, or 57779 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

L2 ANSWER 34 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2003:134569 USPATFULL
TITLE: Novel human enzyme family members and uses thereof
INVENTOR(S): Meyers, Rachel E., Newton, MA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2003092658	A1	20030515
APPLICATION INFO.:	US 2002-175696	A1	20020620 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-67668, filed on 4 Feb 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-266140P	20010202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Intellectual Property Group, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Page(s)	
LINE COUNT:	21384	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 33312, 33303, 32579, 21509, 33770, 46638, and 50090 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33312, 33303, 32579, 21509, 33770, 46638, or 50090 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33312, 33303, 32579, 21509, 33770, 46638, or 50090 gene has been introduced or disrupted. The invention still further provides isolated 33312, 33303, 32579, 21509, 33770, 46638, or 50090 proteins, fusion proteins, antigenic peptides and anti-33312, 33303, 32579, 21509, 33770, 46638, or 50090 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

L2 ANSWER 35 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2003:127069 USPATFULL
TITLE:	18636 receptor, a human G-protein-coupled receptor (GPCR) family member, and uses therefor
INVENTOR(S):	Carroll, Joseph M., Cambridge, MA, UNITED STATES
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087281	A1	20030508
APPLICATION INFO.:	US 2002-226102	A1	20020822 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-314041P	20010822 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Steven A. Bossone, MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	4612	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 18636 nucleic acid molecules, which encode novel G protein coupled receptor family members. The invention also provides antisense nucleic

acid molecules, recombinant expression vectors containing 18636 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636 gene has been introduced or disrupted. The invention still further provides isolated 18636 proteins, fusion proteins, antigenic peptides and anti-18636 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

L2 ANSWER 36 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2002:287589 USPATFULL
TITLE: 25206, a novel human short-chain dehydrogenase/reductase family member and uses thereof
INVENTOR(S): Meyers, Rachel E., Newton, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160452	A1	20021031
APPLICATION INFO.:	US 2001-997816	A1	20011129 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-250186P	20001130 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: P. LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 4862
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 25206 nucleic acid molecules, which encode novel short-chain dehydrogenase/reductase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25206 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25206 gene has been introduced or disrupted. The invention still further provides isolated 25206 proteins, fusion proteins, antigenic peptides and anti-25206 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

L2 ANSWER 37 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2002:148564 USPATFULL
TITLE: 31 human secreted proteins
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
Komatsoulis, George, Silver Spring, MD, UNITED STATES
Endress, Gregory A., Potomac, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002076705	A1	20020620
APPLICATION INFO.:	US 2001-820893	A1	20010330 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-531119, filed on 20

Mar 2000, ABANDONED Continuation-in-part of Ser. No. WO 1999-US22012, filed on 22 Sep 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101546P	19980923 (60)
	US 1998-102895P	19981002 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 17043
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

L2 ANSWER 38 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2002:3832 USPATFULL
TITLE: 21509 and 33770, novel human dehydrogenase family members and uses thereof
INVENTOR(S): Meyers, Rachel A., Newton, MA, UNITED STATES
Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002001807	A1	20020103
APPLICATION INFO.:	US 2001-823901	A1	20010330 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-193920P	20000331 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 5930
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 21509 or 33770 nucleic acid molecules, which encode novel dehydrogenase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21509 or 33770 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21509 or 33770 gene has been introduced or disrupted. The invention still further provides isolated 21509 or 33770 proteins, fusion proteins, antigenic peptides and anti-21509 or 33770 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

=> FIL MEDLINE BIOSIS CAPLUS
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	112.81	113.02

FILE 'MEDLINE' ENTERED AT 17:07:28 ON 05 MAR 2008

FILE 'BIOSIS' ENTERED AT 17:07:28 ON 05 MAR 2008

FILE 'CAPLUS' ENTERED AT 17:07:28 ON 05 MAR 2008

=> s humanized and antibody and CDR and alanine and grafting
L3 3 HUMANIZED AND ANTIBODY AND CDR AND ALANINE AND GRAFTING

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 1 DUP REM L3 (2 DUPLICATES REMOVED)

=> d ibib ab l4

L4 ANSWER 1 OF 1 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 96062076 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7473721
TITLE: Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops.
AUTHOR: Xiang J; Sha Y; Jia Z; Prasad L; Delbaere L T
CORPORATE SOURCE: Saskatoon Cancer Center, Department of Microbiology, Saskatchewan, Canada.
SOURCE: Journal of molecular biology, (1995 Oct 27) Vol. 253, No. 3, pp. 385-90.
Journal code: 2985088R. ISSN: 0022-2836.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199512
ENTRY DATE: Entered STN: 24 Jan 1996
Last Updated on STN: 24 Jan 1996
Entered Medline: 12 Dec 1995

AB Structural analysis derived from the crystallographic study of the chimeric B72.3 antibody illustrated that some heavy-chain framework residues having atomic interactions with heavy-chain CDR residues may directly affect the conformation of CDR loops. For example, an alanine residue at H71 provides room for packing CDR2/CDR1 and lysine residues at H73 and H93 contribute a salt-bridge to aspartic acid at H55 in CDR2 and a hydrogen bond to the carbonyl group at H96 in CDR3, respectively. We have analysed the contribution of these framework residues to the TAG72-binding affinity. We altered these framework residues by site-directed mutagenesis, and determined the affinity of these mutant chimeric antibodies for the TAG72 antigen by solid phase radioimmunoassay. We found that a single amino acid substitution of alanine by phenylalanine at H71 or lysine by isoleucine at H93, significantly reduced the binding affinity for the TAG72 antigen by 12 and 20-fold, respectively, whereas the substitution of lysine by alanine at H73 reduced the binding affinity only two-fold. Our results indicate that heavy-chain framework residues alanine at H71 and lysine at H93 of the chimeric B72.3 antibody are the major determinants of the conformation of

heavy-chain CDR2/CDR1 and CDR3 loops, whereas the salt-bridge between lysine at H73 and aspartic acid at H55 is less important. The hydrogen bond between two framework residues, glutamine at H5 and serine at H25 does not affect any CDR conformation. Our results will thus be of importance especially when the humanized B72.3 antibody is constructed by grafting the CDR loops to a human framework. The important framework region interactions must be maintained in the final humanized antibody.

```
=> FIL STNGUIDE
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              12.98     126.00

FILE 'STNGUIDE' ENTERED AT 17:10:00 ON 05 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 29, 2008 (20080229/UP).

=> s humanized and antibody and SDR and alanine and scanning
             0 HUMANIZED
             0 ANTIBODY
             0 SDR
             0 ALANINE
             0 SCANNING
L5           0 HUMANIZED AND ANTIBODY AND SDR AND ALANINE AND SCANNING

=> FIL MEDLINE BIOSIS CAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.24     126.24

FILE 'MEDLINE' ENTERED AT 17:12:41 ON 05 MAR 2008

FILE 'BIOSIS' ENTERED AT 17:12:41 ON 05 MAR 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 17:12:41 ON 05 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s humanized and antibody and alanine and scanning
L6          22 HUMANIZED AND ANTIBODY AND ALANINE AND SCANNING

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7           9 DUP REM L6 (13 DUPLICATES REMOVED)

=> d ibib ab l7 1-9

L7   ANSWER 1 OF 9     MEDLINE on STN                    DUPLICATE 1
ACCESSION NUMBER:    2007322252     MEDLINE
DOCUMENT NUMBER:     PubMed ID: 17517649
TITLE:               Broadly neutralizing anti-hepatitis B virus
                     antibody reveals a complementarity determining
                     region H3 lid-opening mechanism.
AUTHOR:              Chi Seung-Wook; Maeng Cheol-Young; Kim Seung Jun; Oh Mee
                     Sook; Ryu Chun Jeih; Kim Sang Jick; Han Kyou-Hoon; Hong Hyo
```

Jeong; Ryu Seong Eon
CORPORATE SOURCE: Center for Cellular Switch Protein Structure, Molecular Cancer Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-333, Korea.
SOURCE: Proceedings of the National Academy of Sciences of the United States of America, (2007 May 29) Vol. 104, No. 22, pp. 9230-5. Electronic Publication: 2007-05-17. Journal code: 7505876. ISSN: 0027-8424.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: PDB-2EH7; PDB-2EH8
ENTRY MONTH: 200707
ENTRY DATE: Entered STN: 31 May 2007
Last Updated on STN: 31 Jul 2007
Entered Medline: 30 Jul 2007

AB The humanized monoclonal antibody HzKR127 recognizes the preS1 domain of the human hepatitis B virus surface proteins with a broadly neutralizing activity in vivo. We present the crystal structures of HzKR127 Fab and its complex with a major epitope peptide. In the complex structure, the bound peptide forms a type IV beta-turn followed by 3(10) helical turn, the looped-out conformation of which provides a structural basis for broad neutralization. Upon peptide binding, the antibody undergoes a dramatic complementarity determining region H3 lid opening. To understand the structural implication of the virus neutralization, we carried out comprehensive alanine-scanning mutagenesis of all complementarity determining region residues in HzKR127 Fab. The functional mapping of the antigen-combining site demonstrates the specific roles of major binding determinants in antigen binding, contributing to the rational design for maximal humanization and affinity maturation of the antibody.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:121061 CAPLUS
DOCUMENT NUMBER: 142:217384
TITLE: Human, chimeric and humanized anti-EGFRvIII antibodies, fragments and conjugates for cancer diagnosis and therapy
INVENTOR(S): Weber, Richard; Feng, Xiao; Foord, Orit; Green, Larry; Gudas, Jean; Keyt, Bruce; Liu, Ying; Rathanaswami, Palani; Raya, Robert; Yang, Xiao Dong; Corvalan, Jose; Foltz, Ian; Jia, Xiao-chi; Kang, Jaspal; King, Chadwick T.; Klakamp, Scott L.; Su, Qiaojuan Jane
PATENT ASSIGNEE(S): Abgenix, Inc, USA
SOURCE: PCT Int. Appl., 207 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012479	A2	20050210	WO 2004-US20564	20040625
WO 2005012479	A3	20061012		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2004260936	A1	20050210	AU 2004-260936	20040625
CA	2530172	A1	20050210	CA 2004-2530172	20040625
US	2005053608	A1	20050310	US 2004-877773	20040625
US	2005059087	A1	20050317	US 2004-877774	20040625
EP	1639092	A2	20060329	EP 2004-777147	20040625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR	2004011803	A	20060523	BR 2004-11803	20040625
CN	1930187	A	20070314	CN 2004-80018185	20040625
JP	2007526233	T	20070913	JP 2006-517700	20040625
MX	2005PA14152	A	20060525	MX 2005-PA14152	20051221
IN	2005DN06073	A	20071214	IN 2005-DN6073	20051226

PRIORITY APPLN. INFO.:	US 2003-483145P	P	20030627
	US 2003-525570P	P	20031126
	US 2004-562453P	P	20040415
	WO 2004-US20564	W	20040625

AB The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The antibodies are human, chimeric, humanized monoclonal antibodies, fragments and conjugated or labeled with fluorochrome, enzyme, radionuclide or radiopaque material. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2005:99597 CAPLUS
DOCUMENT NUMBER:	142:196522
TITLE:	Anti-EGFRvIII antibodies, fragments and immunoconjugates for cancer diagnosis and treatment
INVENTOR(S):	Weber, Richard; Feng, Xiao; Foord, Orit; Green, Larry; Gudas, Jean; Keyt, Bruce; Liu, Ying; Rathanaswami, Palani; Raya, Robert; Yang, Xiao Dong; Corvalan, Jose; Foltz, Ian; Jia, Xiao-chi; Kang, Jaspal; King, Chadwick T.; Klakamp, Scott L.; Su, Qiaojuan Jane
PATENT ASSIGNEE(S):	Abgenix, Inc, USA
SOURCE:	PCT Int. Appl., 233 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005010151	A2	20050203	WO 2004-US20295	20040625
WO 2005010151	A3	20050915		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG

AU 2004259398	A1	20050203	AU 2004-259398		20040625
CA 2530285	A1	20050203	CA 2004-2530285		20040625
US 2005053608	A1	20050310	US 2004-877773		20040625
US 2005059087	A1	20050317	US 2004-877774		20040625
EP 1638606	A2	20060329	EP 2004-777034		20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004011852	A	20060523	BR 2004-11852		20040625
CN 1816351	A	20060809	CN 2004-80018260		20040625
JP 2007526880	T	20070920	JP 2006-517620		20040625
MX 2005PA14155	A	20060525	MX 2005-PA14155		20051221
IN 2005DN06074	A	20071214	IN 2005-DN6074		20051226
PRIORITY APPLN. INFO.:			US 2003-483145P	P	20030627
			US 2003-525570P	P	20031126
			US 2004-562453P	P	20040415
			WO 2004-US20295	W	20040625

AB The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to EGFRvIII binding humanized, human, chimeric or monoclonal antibodies, fragments and toxin conjugates for diagnosis and treatment of cancer involving epithelial cell proliferation, such as lung, colon, gastric, renal, prostate, breast, glioblastoma or ovarian carcinoma in human or mammal. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

L7 ANSWER 4 OF 9 MEDLINE on STN DUPLICATE 2

ACCESSION NUMBER:	2002449076 MEDLINE
DOCUMENT NUMBER:	PubMed ID: 12206766
TITLE:	Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody.
AUTHOR:	Gerstner Resi B; Carter Paul; Lowman Henry B
CORPORATE SOURCE:	Department of Protein Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
SOURCE:	Journal of molecular biology, (2002 Aug 30) Vol. 321, No. 5, pp. 851-62. Journal code: 2985088R. ISSN: 0022-2836.
PUB. COUNTRY:	England: United Kingdom
DOCUMENT TYPE:	Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:	English
FILE SEGMENT:	Priority Journals
ENTRY MONTH:	200209
ENTRY DATE:	Entered STN: 4 Sep 2002 Last Updated on STN: 20 Sep 2002 Entered Medline: 19 Sep 2002

AB We have examined the plasticity of the antigen-combining site of a high-affinity antibody. In phage-displayed Fab libraries, selected CDR positions and one FR position of the humanized anti-Her2 antibody hu4D5 were substituted with all 20 amino acids. Antigen-binding selections were used to enrich for high-affinity variants, and a large number of sequences were obtained prior to convergence of the selected pool to a small set of clones. As expected, sequence variability of the antigen-binding site is overall diminished compared to known IgG sequences; however, certain positions retain much higher variability than others. The sequence variability map of the hu4D5 binding site is compared with a map derived from previous alanine -scanning of the antibody. Affinities of soluble Fab fragments for antigen confirm that multiple variants were selected with high affinity for antigen, including one variant with a single point mutation that was about threefold improved in affinity compared to the parental hu4D5. Interestingly, this mutation is one of the most radical

in terms of changing side-chain chemistry (Trp for Asp) and occurs at the most plastic site as calculated by the Wu-Kabat variability coefficient. Thus variability mapping yields information about the antibody -antigen interaction that is useful and complementary to that obtained by alanine scanning mutagenesis.

L7 ANSWER 5 OF 9 MEDLINE on STN DUPLICATE 3
ACCESSION NUMBER: 2002337745 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12079396
TITLE: Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis.
AUTHOR: Vajdos Felix F; Adams Camellia W; Breece Timothy N; Presta Leonard G; de Vos Abraham M; Sidhu Sachdev S
CORPORATE SOURCE: Department of Protein Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
SOURCE: Journal of molecular biology, (2002 Jul 5) Vol. 320, No. 2, pp. 415-28.
Journal code: 2985088R. ISSN: 0022-2836.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200208
ENTRY DATE: Entered STN: 25 Jun 2002
Last Updated on STN: 10 Aug 2002
Entered Medline: 9 Aug 2002

AB Shotgun scanning combinatorial mutagenesis was used to study the antigen-binding site of Fab2C4, a humanized monoclonal antibody fragment that binds to the extracellular domain of the human oncogene product ErbB2. Essentially all the residues in the Fab2C4 complementarity determining regions (CDRs) were alanine-scanned using phage-displayed libraries that preferentially allowed side-chains to vary as the wild-type or alanine. A separate homolog-scan was performed using libraries that allowed side-chains to vary only as the wild-type or a similar amino acid residue. Following binding selections to isolate functional clones, DNA sequencing was used to determine the wild-type/mutant ratios at each varied position, and these ratios were used to assess the contributions of each side-chain to antigen binding. The alanine-scan revealed that most of the side-chains that contribute to antigen binding are located in the heavy chain, and the Fab2C4 three-dimensional structure revealed that these residues fall into two groups. The first group consists of solvent-exposed residues which likely make energetically favorable contacts with the antigen and thus comprise the functional-binding epitope. The second group consists of buried residues with side-chains that pack against other CDR residues and apparently act as scaffolding to maintain the functional epitope in a binding-competent conformation. The homolog-scan involved subtle mutations, and as a result, only a subset of the side-chains that were intolerant to alanine substitutions were also intolerant to homologous substitutions. In particular, the 610 A2 functional epitope surface revealed by alanine-scanning shrunk to only 369 A2 when mapped with homologous substitutions, suggesting that this smaller subset of side-chains may be involved in more precise contacts with the antigen. The results validate shotgun scanning as a rapid and accurate method for determining the functional contributions of individual side-chains involved in protein-protein interactions.

L7 ANSWER 6 OF 9 MEDLINE on STN DUPLICATE 4
ACCESSION NUMBER: 2001495667 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11544314

TITLE: Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction.
AUTHOR: Nisihara T; Ushio Y; Higuchi H; Kayagaki N; Yamaguchi N; Soejima K; Matsuo S; Maeda H; Eda Y; Okumura K; Yagita H
CORPORATE SOURCE: The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan.
SOURCE: Journal of immunology (Baltimore, Md. : 1950), (2001 Sep 15) Vol. 167, No. 6, pp. 3266-75.
Journal code: 2985117R. ISSN: 0022-1767.
PUB. COUNTRY: United States
DOCUMENT TYPE: (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200112
ENTRY DATE: Entered STN: 10 Sep 2001
Last Updated on STN: 22 Jan 2002
Entered Medline: 12 Dec 2001

AB Fas ligand (L)/CD95L, a proapoptotic member of the TNF family, is a potential target for clinical intervention in various diseases. In the present study, we generated a humanized anti-human FasL mAb and characterized the epitopes of neutralizing mAbs by extensive alanine-scanning mutagenesis of human FasL. The predicted molecular model of FasL trimer revealed that the mAbs recognize largely overlapped conformational epitopes that are composed of two clusters, one around the outer tip-forming D-E loop and another near the top of FasL. Both of these sites on FasL are critically involved in the direct interaction with the corresponding receptor, Fas. These results suggest that the mAbs efficiently neutralize FasL cytotoxicity by masking both of these FasL/Fas contact sites.

L7 ANSWER 7 OF 9 MEDLINE on STN DUPLICATE 5
ACCESSION NUMBER: 2001700894 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11741351
TITLE: Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.
AUTHOR: Leong S R; DeForge L; Presta L; Gonzalez T; Fan A; Reichert M; Chuntharapai A; Kim K J; Tumas D B; Lee W P; Gribling P; Snedecor B; Chen H; Hsei V; Schoenhoff M; Hale V; Deveney J; Koumenis I; Shahrokh Z; McKay P; Galan W; Wagner B; Narindray D; Hebert C; Zapata G
CORPORATE SOURCE: Department of Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.. steven.leong@maxygen.com
SOURCE: Cytokine, (2001 Nov 7) Vol. 16, No. 3, pp. 106-19.
Journal code: 9005353. ISSN: 1043-4666.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200203
ENTRY DATE: Entered STN: 20 Dec 2001
Last Updated on STN: 12 Mar 2002
Entered Medline: 11 Mar 2002

AB A neutralizing anti-interleukin-(IL-)8 monoclonal antibody was humanized by grafting the complementary determining regions onto the human IgG framework. Subsequent alanine scanning mutagenesis and phage display enabled the production of an affinity matured antibody with a >100-fold improvement in IL-8 binding. Antibody fragments can be efficiently produced in Escherichia coli

but have the limitation of rapid clearance rates in vivo. The Fab' fragment of the antibody was therefore modified with polyethylene glycol (PEG) in order to obtain a more desirable pharmacokinetic profile. PEG (5-40 kDa) was site-specifically conjugated to the Fab' via the single free cysteine residue in the hinge region. In vitro binding and bioassays showed little or no loss of activity. The pharmacokinetic profiles of the 20 kDa, 30 kDa, 40 kDa, and 40 kDa branched PEG-Fab' molecules were evaluated in rabbits. Relative to the native Fab', the clearance rates of the PEGylated molecules were decreased by 44-175-fold. In a rabbit ear model of ischemia/reperfusion injury, all PEGylated Fab' molecules were as efficacious in reducing oedema as the original monoclonal antibody. These studies demonstrate that it is possible to customize the pharmacokinetic properties of a Fab' while retaining its antigen binding activity.

L7 ANSWER 8 OF 9 MEDLINE on STN DUPLICATE 6
ACCESSION NUMBER: 2000059393 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10590259
TITLE: Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5.
AUTHOR: Zhang J; Kuvelkar R; Murgolo N J; Taremi S S; Chou C C; Wang P; Billah M M; Egan R W
CORPORATE SOURCE: Schering-Plough Research Institute, K-15C113/1600, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA.
SOURCE: International immunology, (1999 Dec) Vol. 11, No. 12, pp. 1935-44.
Journal code: 8916182. ISSN: 0953-8178.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200001
ENTRY DATE: Entered STN: 4 Feb 2000
Last Updated on STN: 8 Oct 2002
Entered Medline: 24 Jan 2000
AB mAb against human IL-5 inhibit pulmonary eosinophilia, tissue damage and airway hyper-reactivity in allergic animal models. Sch 55700 is a humanized, neutralizing anti-IL-5 antibody. To better understand the molecular mechanism by which Sch 55700 blocks IL-5 bioactivity, we have mapped its epitope by scanning IL-5 with synthetic peptides. Those peptides containing a region, ERRRV, corresponding to amino acids 89-93 of IL-5 specifically interact with both Sch 55700 and its parental rat IgG, 39D10. Among the five residues of this region, all three arginine residues were particularly critical for interaction of these peptides with Sch 55700. We further characterized this region by alanine scanning using site-directed mutagenesis. Examination of COS-expressed IL-5 mutants by Western blot showed that single mutations of E(89), R(90), R(91) or R(92) to alanine caused a loss of IL-5 binding to both Sch 55700 and 39D10. We further demonstrated in surface plasmon resonance studies using a BIAcore biosenosor that E(89), R(90) or R(91) are involved in the interaction between IL-5 and its receptor alpha subunit. Based upon the findings here and previously reported structures of the IL-5 and 39D10 variable region, we propose a model suggesting that the molecular interactions between the IL-5 and Sch 55700 mainly involve several ion pair interactions. We conclude that Sch 55700 occupies a region, ERRR, on IL-5 that is essential for its interaction with the receptor and thereby blocks IL-5 bioactivity.

L7 ANSWER 9 OF 9 MEDLINE on STN DUPLICATE 7
ACCESSION NUMBER: 1998428671 MEDLINE

DOCUMENT NUMBER: PubMed ID: 9753694
TITLE: VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.
AUTHOR: Muller Y A; Chen Y; Christinger H W; Li B; Cunningham B C; Lowman H B; de Vos A M
CORPORATE SOURCE: Department of Protein Engineering Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080, USA.
SOURCE: Structure (London, England : 1993), (1998 Sep 15) Vol. 6, No. 9, pp. 1153-67.
Journal code: 101087697. ISSN: 0969-2126.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: PDB-1BJ1; PDB-1BJSF
ENTRY MONTH: 199812
ENTRY DATE: Entered STN: 15 Jan 1999
Last Updated on STN: 15 Jan 1999
Entered Medline: 3 Dec 1998

AB BACKGROUND: Vascular endothelial growth factor (VEGF) is a highly specific angiogenic growth factor; anti-angiogenic treatment through inhibition of receptor activation by VEGF might have important therapeutic applications in diseases such as diabetic retinopathy and cancer. A neutralizing anti-VEGF antibody shown to suppress tumor growth in an in vivo murine model has been used as the basis for production of a humanized version. RESULTS: We present the crystal structure of the complex between VEGF and the Fab fragment of this humanized antibody, as well as a comprehensive alanine-scanning analysis of the contact residues on both sides of the interface. Although the VEGF residues critical for antibody binding are distinct from those important for high-affinity receptor binding, they occupy a common region on VEGF, demonstrating that the neutralizing effect of antibody binding results from steric blocking of VEGF-receptor interactions. Of the residues buried in the VEGF-Fab interface, only a small number are critical for high-affinity binding; the essential VEGF residues interact with those of the Fab fragment, generating a remarkable functional complementarity at the interface. CONCLUSIONS: Our findings suggest that the character of antigen-antibody interfaces is similar to that of other protein-protein interfaces, such as ligand-receptor interactions; in the case of VEGF, the principal difference is that the residues essential for binding to the Fab fragment are concentrated in one continuous segment of polypeptide chain, whereas those essential for binding to the receptor are distributed over four different segments and span across the dimer interface.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.00	144.24
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

FILE 'STNGUIDE' ENTERED AT 17:15:08 ON 05 MAR 2008

```
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 29, 2008 (20080229/UP).

=> d his

     (FILE 'HOME' ENTERED AT 17:03:08 ON 05 MAR 2008)

     FILE 'MEDLINE, BIOSIS, CAPLUS, CA, USPATFULL' ENTERED AT 17:03:30 ON 05
     MAR 2008
L1            38 S CDR AND SDR AND ALANINE AND REPLACING AND AFFINITY AND GRAFTI
L2            38 DUP REM L1 (0 DUPLICATES REMOVED)

     FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 17:07:28 ON 05 MAR 2008
L3             3 S HUMANIZED AND ANTIBODY AND CDR AND ALANINE AND GRAFTING
L4             1 DUP REM L3 (2 DUPLICATES REMOVED)

     FILE 'STNGUIDE' ENTERED AT 17:10:00 ON 05 MAR 2008
L5             0 S HUMANIZED AND ANTIBODY AND SDR AND ALANINE AND SCANNING

     FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 17:12:41 ON 05 MAR 2008
L6            22 S HUMANIZED AND ANTIBODY AND ALANINE AND SCANNING
L7             9 DUP REM L6 (13 DUPLICATES REMOVED)

     FILE 'STNGUIDE' ENTERED AT 17:15:08 ON 05 MAR 2008

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 17:24:15 ON 05 MAR 2008
```